When the CAR-T’s Over: Managing the Long-Term Complications of CAR-T Therapy

<p>Alejandro Del Rio Verduzco, PharmD (Twitter: <a href='https://twitter.com/Alejandro_DRV'>@Alejandro_DRV</a>) defines the different short-term and long-term toxicities of CAR-T therapy, describes evidence for existing management strategies for late-term CAR-T toxicities and identifies evidence and reports of emerging late-term CAR-T toxicities.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>